These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27282075)

  • 1. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.
    Kirby MK; Ramaker RC; Gertz J; Davis NS; Johnston BE; Oliver PG; Sexton KC; Greeno EW; Christein JD; Heslin MJ; Posey JA; Grizzle WE; Vickers SM; Buchsbaum DJ; Cooper SJ; Myers RM
    Mol Oncol; 2016 Oct; 10(8):1169-82. PubMed ID: 27282075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
    Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
    Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
    Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
    Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
    Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
    Song Y; Zou L; Li J; Shen ZP; Cai YL; Wu XD
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8161-8168. PubMed ID: 30556854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
    Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
    Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma.
    Wei W; Hu Q; Li W; Li M; Dong S; Peng Y; Yin J; Lu Y; Liu L; Zhao Q
    DNA Cell Biol; 2022 Feb; 41(2):116-127. PubMed ID: 34898275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
    Phua LC; Goh S; Tai DWM; Leow WQ; Alkaff SMF; Chan CY; Kam JH; Lim TKH; Chan ECY
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):277-289. PubMed ID: 29196965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
    Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
    World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
    Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
    Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
    World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
    Xie H; Jiang W; Xiao SY; Liu X
    J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
    Karelia DN; Kim S; K Pandey M; Plano D; Amin S; Lu J; Sharma AK
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.